Clinical trial
An Exploratory, Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder
NCT04745026 is registered in ClinicalTrials.gov with Jazz Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Exploratory, Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder
- Lead sponsor
- Jazz Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 31, 2021
- Completion date
- December 21, 2023
- Enrollment
- 103 (actual)
- Sites
- 23
Conditions
As the registry lists them; a condition with its own page is linked.